HBOT Conversations:

Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy

Subscribe. Join the discussion. Share the hope.

 

 

 

Listen to or Watch the HBOT Conversations Podcast

Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:

Watch the HBOT Conversations Podcast

Laurie Anderson – Healing COVID with HBOT (Part 3)

Laurie Anderson – Healing COVID with HBOT (Part 3)

Laurie Anderson – Healing COVID with HBOT (Part 2)

Laurie Anderson – Healing COVID with HBOT (Part 2)

Laurie Anderson – Healing COVID with HBOT (Part 1)

Laurie Anderson – Healing COVID with HBOT (Part 1)

Tom Fox (Part 2)

Tom Fox (Part 2)

Tom Fox (Part 1)

Tom Fox (Part 1)

Elena Schertz & Tom Fox (Part 5)

Elena Schertz & Tom Fox (Part 5)

Elena Schertz & Tom Fox (Part 4)

Elena Schertz & Tom Fox (Part 4)

Elena Schertz & Tom Fox (Part 3)

Elena Schertz & Tom Fox (Part 3)

Elena Schertz & Tom Fox (Part 2)

Elena Schertz & Tom Fox (Part 2)

Elena Schertz & Tom Fox (Part 1)

Elena Schertz & Tom Fox (Part 1)

Dr. Jay Stevens  – Optimizing Health & Longevity

Dr. Jay Stevens – Optimizing Health & Longevity

Evan Fernandez – Warriors on the Water

Evan Fernandez – Warriors on the Water

Dr. Jay Stevens  – Head Injuries

Dr. Jay Stevens – Head Injuries

Jim Hooker – HBOT for Vets (Part 2)

Jim Hooker – HBOT for Vets (Part 2)

Jim Hooker – HBOT for Vets (Part 1)

Jim Hooker – HBOT for Vets (Part 1)

Dr. Hemal Mehta & Vibrant Health University

Dr. Hemal Mehta & Vibrant Health University

Dr. Jay Stevens  – Sports-Related Injuries & Performance Enhancement

Dr. Jay Stevens – Sports-Related Injuries & Performance Enhancement

Ernie Harrison: Veteran with PTSD & TBI

Ernie Harrison: Veteran with PTSD & TBI

Dr. Hemal Mehta & Regenerative Medicine

Dr. Hemal Mehta & Regenerative Medicine

Dr. Hemal Mehta & Fasting (Part 2)

Dr. Hemal Mehta & Fasting (Part 2)

Dr. Hemal Mehta & Fasting (Part 1)

Dr. Hemal Mehta & Fasting (Part 1)

Dr. Jay Stevens – “Learn The Right Fast”

Dr. Jay Stevens – “Learn The Right Fast”

Dr. Peter Canaday (Part 2)

Dr. Peter Canaday (Part 2)

Dr. Peter Canaday (Part 1)

Dr. Peter Canaday (Part 1)

Dr. Paul Harch & Viral / Bacterial Infections

Dr. Paul Harch & Viral / Bacterial Infections

Dr. Paul Harch & 8,101 Genes

Dr. Paul Harch & 8,101 Genes

Dr. Paul Harch & Autism

Dr. Paul Harch & Autism

Dr. Paul Harch & Strokes

Dr. Paul Harch & Strokes

Dr. Paul Harch & Birth Injuries/ Cerebral Palsy

Dr. Paul Harch & Birth Injuries/ Cerebral Palsy

Dr. Paul Harch & The Science Behind the Practice

Dr. Paul Harch & The Science Behind the Practice

Dr. Paul Harch & TBI

Dr. Paul Harch & TBI

Dr. Paul Harch & Thermal Burns

Dr. Paul Harch & Thermal Burns

Dr. Paul Harch & Inflammation

Dr. Paul Harch & Inflammation

Robert Beckman & TreatNow.org

Robert Beckman & TreatNow.org

Elena Schertz & Extivita RTP

Elena Schertz & Extivita RTP

Subscribe Now, It’s Free !

Name(Required)

Recent HBOT News

Clinical Trial – Radiation Induced Cystitis Treated With Hyperbaric Oxygen – A Randomized Controlled Trial

The primary objective of this study is to assess the relief of symptoms after Hyperbaric
Oxygen Therapy (HBOT) in patients with late radiation cystitis by having Expanded Prostate
cancer Index Composite (EPIC)symptom estimation scale as primary variable.

Study hypothesis:

– HBOT can reduce or reverse the change or otherwise limit the damage of the bladder
function and/or structure, which arose as a result of radiation therapy of cancer in the
pelvic region organs.

– The effects of HBOT are associated with relief of symptoms that, at least in part, is
related to the reduction of the extent of the radiation damage.

– Vascular density increases, fibrosis prevalence and inflammatory activity are reduced as
a sign of an improved function of the mucosa.

– Treatment results of HBOT remains, in whole or in part, during the follow-up (residual
effect)

Clinical Trial – Effective Dose of Dexmedetomidine for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia With or Without Fentanyl by Age Groups: Randomized Comparative Study

Recently many studies reported that intraoperative dexmedetomidine administration undergoing
spinal anesthesia give a satisfactory sedation in elderly patients and cause less respiratory
depressions compared other sedatives(e.g. benzodiazepine) But the optimal dose of
dexmedetomidine for sedative effect in elderly patients undergoing spinal anesthesia was not
got general consensus.

The investigators hypothesized that the dose requirements would be lower than in elderly
patients than young patients. Furthermore, intrathecal small dose opioids enhance the
analgesia provided by bupivacaine due to synergistic effects and it would reduce the dose of
dexmedetomidine.

The purpose of this study was to determine the dose of dexmedetomidine to provide
satisfactory sedation undergoing spinal anesthesia with or without additive small dose
intrathecal opioids.

Elderly patients(65~85 years old) undergoing TURP or TURB were enrolled in this
single-blinded study. Forty patients were randomly assigned to receive intrathecal hyperbaric
bupivacaine 6mg coadministered with 20mcg fentanyl or placebo normal saline 0.4cc. After the
induction (bilateral T10 sensory level to pinprick within 5 mins of intrathecal drug
administration), continuous intravenous dexmedetomidine was started in dose of 0.8, 0.6, 0.5,
0.4, 0.3, or 0.2mcg. Successful sedation was defined as OASS score 3 or 4 within 20 minutes
of dexmedetomidine infusion. The dose of dexmedetomidine was selected for each patient
according to an up and down method. Intraoperative arterial pressure, heart rate, and
bispectral index was compared. Postoperative pain score, the time for the regression of
sensory and motor was recorded for further analysis.